Oncology Medical News about multiple myeloma;plerixafor

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization
Bone Marrow Transplantation, 06/24/09

Tricot G et al. - In a trial to assess the safety and efficacy of plerixafor for stem cell mobilization and tumor cell contamination, it was established that the safety profile of plerixafor in all pts was consistent with previous reports.

Methods

This was an open-label, single-center, phase II study of 20 pts with multiple myeloma (MM) who were either proven poor mobilizers (n=10; group A) or predicted poor mobilizers (n=10; group B) and were planned for autologous hematopoietic SCT.

Results

Peripheral blood (PB) CD34+ cell count was generally very low pre- plerixafor and increased significantly post-plerixafor administration.
Cumulative apheresis yields of ≥2 x 106 CD34+ cells/kg were observed in 7 of 10 pts (group A) and 8 of 10 pts (group B).
Among the proven poor mobilizers, there was no evidence of tumor cell mobilization in the PB after G-CSF plus plerixafor treatment.
17 of 20 (85%) pts underwent transplantation.
Neutrophil engraftment occurred at a median of 13 days for all pts.
Platelet engraftment occurred at a median of 16 days and 19 days for all proven and predicted poor mobilizers, respectively.
At 12 mos, 12 of 17 pts had documented durable grafts, 3 of 17 pts died and 2 of 17 pts were lost to follow-up; but they had documented graft durability at the previous 3- and 6-mo visit.

<< Previous
KIF11 inhibition for glioblastoma treatment: reason to hope or a...

Next >>
Meat and egg consumption and risk of breast cancer among Chinese...

Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09 Relevance Score: 69%

Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09 Relevance Score: 69%

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09 Relevance Score: 69%

An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Anticancer Research, 11/13/09 Relevance Score: 67%

Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma
Annals of Hematology, 10/27/09 Relevance Score: 67%